|
|
| Line 14: |
Line 14: |
| | | | | |
| |} | | |} |
| {| class="wikitable" style="text-align: center; margin-left: auto; margin-right: auto; font-size: 125%; font-weight: bold; width: 100%; height: 93px;" | | {| class="wikitable sortable mw-collapsible" style="text-align: center; margin-left: auto; margin-right: auto; font-size: 125%; font-weight: bold; width: 100%; height: 93px;" |
| | |+ |
| |- style="height: 65px;" | | |- style="height: 65px;" |
| | style="width: 10%; font-size: 125%; background-color: rgb(8, 81, 156); height: 65px;" | <span style="color:white;"><span style="color: black;" >[[Guidelines]]</span></span> | | | style="width: 10%; font-size: 125%; background-color: rgb(8, 81, 156); height: 65px;" | <span style="color:white;"><span style="color: black;">[[Guidelines]]</span></span> |
| | style="width: 10%; font-size: 125%; background-color: rgb(8, 81, 156); height: 65px;" | [[#solidtumors|<span style="color:white;">Solid Tumors</span>]] | | | style="width: 10%; font-size: 125%; background-color: rgb(8, 81, 156); height: 65px;" | [[#solidtumors|<span style="color:white;">Solid Tumors</span>]] |
| | |Hematological Neoplasms |
| |- style="height: 28px;" | | |- style="height: 28px;" |
| | style="width: 10%; height: 28px;" | | | | style="width: 10%; height: 28px;" | |
| | style="width: 10%; height: 28px;" | | | | style="width: 10%; height: 28px;" | |
| | | |
| |} | | |} |
|
| |
|
<span class="mwt-editable mwt-comment" id="R1766923378676" " draggable="false" contenteditable="true">Hides title of Main Page
Neoplasm.org is a collaborative, open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens.
Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.
| Solid Tumors
|
| Breast Oncology
|
| Early breast cancer (EBC)
|
| EBC, NOS
|
HR-positive EBC
|
HER2-positive EBC
|
HER2-low EBC
|
| HR-positive and HER2-positive EBC
|
Early triple-negative breast cancer (eTNBC)
|
| Metastatic breast cancer (MBC)
|
| MBC, NOS
|
HR-positive MBC
|
HER2-positive MBC
|
HER2-low MBC
|
| HR-positive and HER2-positive MBC
|
Metastatic triple-negative breast cancer (mTNBC)
|
CNS metastases
|
| Breast cancer with molecular alterations
|
| Testfdasfjifojifjo
|
PI3K pathway-altered Breast cancer
|
| Dermatologic Oncology
|
| Melanoma
|
| Melanoma, NOS
|
BRAF-mutated Melanoma
|
KIT-mutated Melanoma
|
NRAS-mutated Melanoma
|
| Uveal melanoma
|
| Non-melanoma skin cancer (NMSC)
|
| Cutaneous BCC
|
Cutaneous SCC
|
Merkel cell carcinoma (MCC)
|
| Endocrine Oncology
|
| Other endocrine cancers
|
| Adrenocortical carcinoma
|
Neuroendocrine tumor (NET)
|
Neuroendocrine carcinoma (NEC)
|
Pancreatic NET
|
| Pheochromocytoma
|
| Thyroid cancer without molecular alterations
|
| Thyroid cancer, NOS
|
Anaplastic thyroid cancer (ATC)
|
Differentiated thyroid cancer (DTC)
|
Medullary thyroid cancer (MTC)
|
| Thyroid cancer with molecular alterations
|
| BRAF-mutated Thyroid cancer
|
RET-positive Thyroid cancer
|
| Gastrointestinal Oncology
|
| Upper GI tract
|
| Esophageal cancer, NOS
|
Esophageal adenocarcinoma
|
Esophageal squamous cell carcinoma (ESCC)
|
Gastric cancer, NOS
|
| HER2-positive gastric cancer
|
| Lower GI tract
|
| Anal cancer
|
Appendiceal tumor
|
Colon cancer, NOS
|
RAS wild-type colon cancer
|
| Colorectal cancer (CRC), NOS
|
BRAF-mutated CRC
|
HER2-positive CRC
|
MSI-H or dMMR CRC
|
| RAS wild-type CRC
|
Rectal cancer
|
Small bowel adenocarcinoma
|
| Hepatobiliary cancer
|
| Biliary tract cancer
|
Cholangiocarcinoma
|
Gallbladder cancer
|
Hepatocellular carcinoma (HCC)
|
| Periampullary adenocarcinoma
|
| Pancreatic cancer
|
| Pancreatic adenocarcinoma, NOS
|
BRCA-mutated Pancreatic adenocarcinoma
|
NRG1-positive Pancreatic adenocarcinoma
|
Pancreatic NET
|
| Genitourinary Oncology
|
| Kidney cancer
|
| Renal cell carcinoma (RCC), NOS
|
Clear cell RCC (ccRCC)
|
Non-clear cell RCC (nccRCC)
|
Papillary RCC
|
| Sarcomatoid RCC
|
VHL-associated RCC
|
| Male genital tract
|
| Penile cancer
|
Prostate cancer, NOS
|
Prostate cancer, HRD-positive
|
Testicular cancer
|
| Urinary tract cancer
|
| Urothelial carcinoma, NOS
|
Bladder cancer
|
Upper tract urothelial carcinoma (UTUC)
|
| Gynecologic Oncology
|
| Ovarian cancer
|
| High-grade serous ovarian cancer (HGSOC)
|
Low-grade serous ovarian cancer (LGSOC)
|
Ovarian cancer, BRCA-mutated
|
| Other gynecologic cancer
|
| Cervical cancer
|
Endometrial cancer
|
Gestational trophoblastic neoplasia
|
Vulvar cancer
|
| Head & Neck Oncology
|
| Head and neck cancer
|
Nasopharyngeal carcinoma (NPC)
|
HPV+ Oropharyngeal cancer
|
| Mesothelioma
|
| Malignant peritoneal mesothelioma (MPEM)
|
Malignant pleural mesothelioma (MPM)
|
| Neuro-Oncology
|
| Primary central nervous system (CNS) malignancies
|
| Anaplastic glioma
|
Craniopharyngioma
|
Diffuse midline glioma New
|
Glioblastoma (GBM)
|
| Low-grade glioma
|
Meningioma
|
Subependymal giant cell astrocytoma (SEGA)
|
| Secondary CNS malignancies
|
| CNS carcinoma
|
CNS leukemia
|
CNS lymphoma
|
CNS melanoma
|
| Sarcoma
|
| Bone sarcoma
|
| Bone sarcoma, NOS
|
Ewing sarcoma
|
Giant-cell tumor of bone
|
Osteosarcoma
|
| Soft tissue sarcoma
|
| Soft tissue sarcoma (STS), NOS
|
Alveolar soft part sarcoma (ASPS)
|
Dermatofibrosarcoma protuberans
|
Desmoid tumor
|
| Epithelioid sarcoma
|
Gastrointestinal stromal tumor (GIST)
|
Inflammatory myofibroblastic tumor (IMT)
|
Leiomyosarcoma (LMS)
|
| Liposarcoma
|
PEComa
|
Rhabdomyosarcoma (RMS)
|
Tenosynovial giant cell tumor (TGCT)
|
| Vascular sarcoma
|
| Vascular sarcoma, NOS
|
Angiosarcoma
|
Kaposi sarcoma (KS)
|
| Thoracic Oncology
|
| Non-small cell lung cancer (NSCLC) without driver alterations
|
| NSCLC, NOS
|
Nonsquamous NSCLC
|
Squamous NSCLC
|
PD-L1-positive NSCLC
|
| CNS metastases
|
| NSCLC with driver alterations
|
| ALK-positive NSCLC
|
BRAF-mutated NSCLC
|
c-Met-positive NSCLC
|
EGFR-mutated NSCLC
|
| HER2-mutated NSCLC
|
KRAS-mutated NSCLC
|
MET-mutated NSCLC
|
NRG1-positive NSCLC
|
| RET-positive NSCLC
|
ROS1-positive NSCLC
|
| Other thoracic cancer
|
| Malignant pleural mesothelioma (MPM)
|
Small cell lung cancer (SCLC)
|
Thymoma
|
| Site-agnostic
|
| BRAF
|
EGFR
|
ERBB2 (HER2)
|
ERBB3 (HER3)
|
| MSI-H or dMMR
|
NTRK
|
RET
|
SMO or PTCH-1 (Hedgehog)
|
| TMB-H
|
Carcinoma of unknown primary (CUP)
|
| Malignant Hematology
|
| Acute leukemias
|
| Acute leukemia, KMT2A-rearranged
|
Acute myeloid leukemia (AML)
|
AML, FLT3-positive
|
AML, IDH-mutated
|
| AML, NPM1-mutated
|
Acute promyelocytic leukemia (APL)
|
B-cell acute lymphoblastic leukemia (B-ALL)
|
B-ALL, Ph+
|
| T-cell acute lymphoblastic leukemia (T-ALL)
|
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
|
CNS leukemia
|
| Myeloproliferative neoplasms and myelodysplastic syndromes
|
| Chronic myeloid leukemia (CML)
|
Chronic myelomonocytic leukemia (CMML)
|
Essential thrombocythemia (ET)
|
Hypereosinophilic syndrome (HES)
|
| Myelodysplastic syndrome (MDS)
|
Primary & secondary myelofibrosis (PMF/SMF)
|
Myeloproliferative neoplasm, accelerated phase (MPN-AP) New
|
Polycythemia vera (PV)
|
| Systemic mastocytosis
|
| Aggressive lymphomas
|
| Burkitt lymphoma (BL) or Burkitt-like lymphoma
|
Classical Hodgkin lymphoma (cHL)
|
CNS lymphoma
|
Diffuse large B-cell lymphoma (DLBCL)
|
| Gastric DLBCL New
|
High-grade B-cell lymphoma (HGBL)
|
HIV-associated lymphoma
|
Mantle cell lymphoma (MCL)
|
| Mediastinal gray-zone lymphoma (MGZL)
|
Primary mediastinal B-cell lymphoma (PMBL)
|
Transformed lymphoma (TL)
|
| Indolent lymphomas
|
| Chronic lymphocytic leukemia (CLL/SLL)
|
Follicular lymphoma (FL)
|
Hairy cell leukemia (HCL)
|
Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
|
| Indolent lymphoma (iNHL)
|
MALT lymphoma
|
Marginal zone lymphoma (MZL)
|
Waldenström macroglobulinemia (WM/LPL)
|
| Plasma cell dyscrasias
|
| Light-chain (AL) amyloidosis
|
Multiple myeloma (main page)
|
MM, induction
|
MM, consolidation & maintenance
|
| MM, relapsed/refractory
|
Plasma cell leukemia (PCL)
|
POEMS syndrome
|
Smoldering multiple myeloma (SMM)
|
| T-cell and NK-cell neoplasms
|
| Adult T-cell leukemia-lymphoma (ATLL)
|
Anaplastic large cell lymphoma (ALCL)
|
Cutaneous T-cell lymphoma (CTCL)
|
Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
|
| Large granular lymphocytic (LGL) leukemia
|
NK- and T-cell lymphoma (NKTCL)
|
Peripheral T-cell Lymphoma (PTCL)
|
T-cell acute lymphoblastic lymphoma (T-LBL)
|
| T-cell prolymphocytic lymphoma (T-PLL)
|
| Lymphoproliferative disorders
|
| Castleman disease
|
Post-transplant lymphoproliferative disorder (PTLD)
|
| Histiocytic disorders
|
| Erdheim-Chester disease (ECD)
|
Hemophagocytic lymphohistiocytosis (HLH)
|
Langerhans cell histiocytosis (LCH)
|
Rosai-Dorfman-Destombes disease
|
What We Do
In the fast-moving field of oncology, keeping up with the latest data is a challenge. Neoplasm.org serves as a "living textbook" where:
Clinical Trial Results are summarized and categorized for quick reference.
Treatment Regimens are detailed with evidence-backed citations and toxicity profiles.
Collaborative Note-taking allows experts to contribute clinical pearls and real-world experience.
Why Neoplasm.org?
Unlike static journals, our platform is built for speed and collaboration. Using modern collaborative tools (powered by Docmost), we allow credentialed contributors to update notes in real-time as new data emerges from ASCO, ESMO, and major journals.
Free to the Public: Information that saves lives should not be behind a paywall.
Clinically Structured: Organized by disease site, histology, and stage for maximum utility during rounds or tumor boards.
Evidence-Based: Every note is rooted in published clinical evidence.
Join the Collaboration
Neoplasm.org is built by the oncology community, for the oncology community. Whether you are adding a new regimen or refining a trial summary, your contributions help build a more transparent and informed world for cancer care.
Disclaimer: Neoplasm.org is an educational and research resource. Clinical decisions should always be made by a qualified healthcare professional.
